A THOUSAND OR TWO TO A THOUSAND. THANK YOU.
THANK YOU. >> WE’LL DO QUESTIONS.
>> THANK YOU, MR. VICE
PRESIDENT.
PRESIDENT. I’M GOING CHANGE THE TOPIC JUST
A LITTLE BIT BECAUSE THERE WAS A
QUESTION THAT CAME UP AND I’VE
BEEN ASKED ABOUT THIS ON A
COUPLE OF MEDIA INTERACTIONS
REGARDING THE INTERVENTIONS
WE’RE TALKING ABOUT.
AND IT’S IMPORTANT, BECAUSE IT’S
ABOUT SOMETHING THAT I SAID
YESTERDAY ABOUT WHAT WE WOULD
LIKELY SEE WHENEVER YOU PUT THE
CLAMPS DOWN AND SHUT THINGS
DOWN, YOU DO IT FOR TWO REASONS.
YOU DO IT TO PREVENT THE FURTHER
SPREAD.
SPREAD. WE CALL MITIGATION.
BUT YOU ALSO DO IT TO BUY
YOURSELF TIME TO GET BETTER
PREPARED FOR WHAT MIGHT BE A
REBOUND.
REBOUND. IT MAY BE A REBOUND THAT WE GET
THINGS REALLY UNDER CONTROL, AND
THEN YOU PULL BACK, WHICH
ULTIMATELY WE’RE GOING TO HAVE
TO DO.
TO DO. NERVE THE WORLD GOING TO HAVE TO
DO THAT.
DO THAT. YOU EITHER GET A REBOUND, OR IT
MIGHT CYCLE INTO THE NEXT
SEASON.
SEASON. SO WHAT ARE WE GOING TO DO TO
PREPARE OURSELVES FOR THAT?
ONE OF THE MOST IMPORTANT THINGS
IS ONE THAT I MENTIONED SEVERAL
TIMES FROM THIS PODIUM.
AND THAT IS TO CLARIFY A BIT
ABOUT THE TIMELINE FOR VACCINES.
AND WITH THAT HAVE ANY REAL
IMPACT ON WHAT WE WOULD CALL THE
REBOUNDS OR WHAT WE WOULD CALL
THE CYCLING IN THE SEASON.
CERTAINLY FOR SURE A VACCINE IS
NOT GOING TO HELP US NOW NEXT
MONTH, THE MONTH AFTER.
BUT AS I MENTIONED TO YOU, WE
WENT INTO A PHASE 1 TRIAL.
AND I KEEP REFERRING TO ONE
VACCINE.
VACCINE. THERE IS MORE THAN ONE.
THERE IS A COUPLE OF HANDFULS OF
VACCINES AT DIFFERENT STAGES OF
DEVELOPMENT.
DEVELOPMENT. BUT THEY’RE ALL FOLLOWING THE
SAME COURSE.
SAME COURSE. AND THE COURSE IS YOU FIRST GO
IN TO A PHASE 1 TRIAL TO SEE IF
IT’S SAFE, AND YOU HAVE VERY FEW
PEOPLE, 45 PEOPLE WITHIN A
CERTAIN AGE GROUP, ALL HEALTHY,
NONE AT REALLY ANY GREAT RISK OF
GETTING INFECTED.
GETTING INFECTED. THE REASON YOU DO THAT, BECAUSE
YOU WANT TO MAKE SURE THAT IT’S
SAFE.
SAFE. AND THE NEXT THING YOU DO, AND
THAT TAKES ABOUT THREE MONTHS,
EASILY, MAYBE MORE.
SO THAT’S GOING TO BRING SEXUAL
ABUSE THE BEGINNING OR MIDDLE OF
THE SUMMER.
THE SUMMER. THEN YOU GO TO A PHASE 2 TRIAL,
OR WHAT WE SAY 2-3, WHICH MEANS
WE’RE GOING TO PUT A LOT OF
PEOPLE IN THERE.
NOW WE HOPE THAT THERE AREN’T A
LOT OF PEOPLE GETTING INFECTED.
BUT IT IS LIKELY THERE WILL BE
SOMEWHERE IN THE WORLD WHERE
THAT’S GOING ON.
SO IT’S LIKELY THAT WE WILL GET
WHAT’S CALLED AN EFFICACY
SIGNAL.
SIGNAL. AND WE WILL KNOW WHETHER OR NOT
IT ACTUALLY WORKS.
IF IN FACT IT DOES, WE HOPE IT
IS ABLE TO HAVE SOME IMPACT ON
RECYCLING IN THE NEXT SEASON.
LIKE I SAID, THAT COULD BE A
YEAR TO A YEAR AND A HALF.
I’M NOT CHANGING ANY OF THE
DATES THAT I MENTIONED.
BUT ONE OF THE THINGS THAT WE
ARE GOING TO DO THAT YOU NEED TO
UNDERSTAND THAT HAS BEEN A
STUMBLING BLOCK FOR PREVIOUS
DEVELOPMENT OF VACCINES, AND
THAT IS EVEN BEFORE YOU KNOW
SOMETHING WORKS, AT RISK YOU
HAVE TO START PRODUCING IT.
BECAUSE ONCE YOU KNOW IT WORKS,
YOU CAN’T SAY GREAT, IT WORKS.
NOW GIVE ME ANOTHER SIX MONTHS
TO PRODUCE IT.
SO WE’RE WORKING WITH A VARIETY
OF COMPANIES TO TAKE THAT RISK
WE DIDN’T TAKE IT WITH ZIKA.
WE HAVE A NICE ZIKA VACCINE, BUT
WE DON’T HAVE ENOUGH TO DO IT
BECAUSE WE DON’T HAVE ENOUGH
ZIKA AROUND.
ZIKA AROUND. THE SAME WITH SARS.
THAT’S ONE OF THE THINGS WE’RE
REALLY GOING TO BE ABLE TO PUSH
ON IS TO HAVE IT READY IN CASE
IT WORKS.
IT WORKS. NOW, THE ISSUE OF SAFETY.
SOMETHING I WANT TO MAKE SURE
THAT THE AMERICAN PUBLIC
UNDERSTAND.
UNDERSTAND. IT’S NOT ONLY SAFETY WHEN YOU
INJECT SOMEBODY AND THEY GET
MAYBE AN IDIOSYNCRATIC REACTION,
THEY GET A LITTLE ALLERGIC
REACTION, THEY GET PAIN.
THERE IS SAFETY ASSOCIATED, DOES
THE VACCINE MAKE YOU WORSE.
AND THERE ARE DISEASES IN WHICH
YOU VACCINATE SOMEONE, THEY GET
INFECTED WITH WHAT YOU’RE TRYING
TO PROTECT THEM WITH AND YOU
ACTUALLY ENHANCE THE INFECTION.
YOU CAN GET A GOOD FEEL FOR THAT
IN ANIMAL MODELS.
THAT’S GOING TO BE INTERSPERSED
AT THE SAME TIME THAT WE’RE
TESTING, WE’RE GOING TRY AND
MAKE SURE WE DON’T HAVE
ENHANCEMENT.
ENHANCEMENT. THAT’S THE WORST POSSIBLE THING
YOU CAN DO IS VACCINATE SOMEBODY
TO PREVENT INFECTION AND
ACTUALLY MAKE THEM WORSE.
NEXT, AND FINALLY, I’LL GET TO
YOUR QUESTION.
YOUR QUESTION. FINALLY, WITH REGARD TO
THERAPIES, I MEAN, WE KEEP
GETTING ASKED ABOUT THERAPIES.
THERE IS A WHOLE MENU OF
THERAPIES THAT ARE GOING INTO
CLINICAL TRIAL.
CLINICAL TRIAL. AS I’VE TOLD YOU ALL AND
REPEATED AGAIN, THE BEST WAY TO
GET THE BEST DRUG AS QUICKLY AS
POSSIBLE IS TO DO A RANDOMIZED
CONTROLLED TRIAL SO THAT YOU
KNOW IS IT SAFE AND IS IT
EFFECTIVE.
EFFECTIVE. IF IT’S NOT EFFECTIVE, GET IT
OFF THE BOARD AND GO TO THE NEXT
THING.
THING. IF IT IS EFFECTIVE, GET IT OUT
TO THE PEOPLE THAT NEED IT.
SO YOU’RE GOING TO BE HEARING
OVER THE NEXT MONTH OR MORE
ABOUT DIFFERENT DRUGS THAT ARE
GOING TO GO INTO THESE
RANDOMIZED CONTROL TRIALS.
AND I FEEL CONFIDENT KNOWING
ABOUT WHAT THIS VIRUS IS AND
WHAT WE CAN DO WITH IT THAT WE
WILL HAVE SOME SORT OF THERAPY
THAT GIVE AT LEAST A PARTIAL, IF
NOT A VERY GOOD PROTECTION IN